Microbix Biosystems - MBX Stock Forecast, Price & News

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Analyst Ratings Changes

Separately, Bloom Burton restated a "buy" rating on shares of Microbix Biosystems in a research note on Monday, June 6th.

Microbix Biosystems Price Performance

Shares of TSE:MBX remained flat at C$0.52 during trading hours on Friday. The company had a trading volume of 9,500 shares, compared to its average volume of 59,944. The stock has a fifty day moving average price of C$0.50 and a two-hundred day moving average price of C$0.54. The company has a current ratio of 6.49, a quick ratio of 4.71 and a debt-to-equity ratio of 26.68. The company has a market capitalization of C$71.20 million and a P/E ratio of 17.33. Microbix Biosystems has a twelve month low of C$0.41 and a twelve month high of C$0.87.

Microbix Biosystems (TSE:MBX - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported C$0.01 earnings per share for the quarter. The company had revenue of C$4.88 million during the quarter. Sell-side analysts forecast that Microbix Biosystems will post 0.04 earnings per share for the current fiscal year.

Insider Transactions at Microbix Biosystems

In other news, Director Cameron Lionel Groome sold 65,000 shares of the company's stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of C$0.52, for a total transaction of C$33,540.00. Following the transaction, the director now owns 625,000 shares of the company's stock, valued at C$322,500.